Pages

▼
Showing posts with label Inflation Reduction Act of 2022. Show all posts
Showing posts with label Inflation Reduction Act of 2022. Show all posts
Wednesday, October 14, 2026

10 Crucial Trends Facing U.S. Drug Wholesalers in 2026 and Beyond

›
By Adam J. Fein, Ph.D. As regular readers of Drug Channels know, U.S. distribution and dispensing channels for prescription drugs are unde...
Thursday, October 08, 2026

The IRA Fixed One Medicare Part D Distortion—But Patients Now Face New Tradeoffs (rerun)

›
This week, we're rerunning some popular posts while we put the finishing touches on DCI’s 2026-27 Economic Report on Pharmaceutical Whol...
Tuesday, August 04, 2026

Who Will Pay for Prescription Drugs in 2034? Medicare's Surprising Rise in the Latest Government Forecasts

›
By Adam J. Fein, Ph.D. and Greis Kapexhiu In late June, the boffins at the Centers for Medicare & Medicaid Services (CMS) released the...
Wednesday, July 15, 2026

The 340B Program Hit $100 Billion in 2025: Has It Become Too Big to Reform?

›
By Adam J. Fein, Ph.D. The 340B Drug Pricing Program continues to redefine the meaning of "skyrocketing." For 2025, discounted pu...
Tuesday, June 16, 2026

The IRA Fixed One Medicare Part D Distortion—But Patients Now Face New Tradeoffs

›
By Bryce Platt, PharmD For years, Medicare Part D plans often preferred high-list/high-rebate branded multiple sclerosis (MS) drugs over l...
Wednesday, April 08, 2026

List Price Reductions Will Deflate the Gross-to-Net Bubble–and Threaten Pharmacy and 340B Profits from IRA-Negotiated Drugs (rerun)

›
This week, I’m rerunning some popular posts while we prepare for Friday’s live video webinar: PBM Industry Update 2026: Trends, Challenges, ...
Tuesday, March 03, 2026

Preorder Now: DCI’s 2026 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers

›
On March 24, 2026, Drug Channels Institute will release The 2026 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers . This re...
Tuesday, February 03, 2026

Latest CMS Data Reveal Six Trends Reshaping U.S. Drug Spending

›
By Adam J. Fein, Ph.D. The boffins at the Centers for Medicare & Medicaid Services (CMS) recently dropped the latest National Health Exp...
Wednesday, January 07, 2026

U.S. Brand-Name Drug Prices Fell in 2025 as the Net Pricing Drug Channel Emerges

›
By Adam J. Fein, Ph.D. It's time for Drug Channels ’ annual examination of U.S. brand-name drug pricing. For 2025, brand-name drugs’ av...
Thursday, December 18, 2025

Drug Channels News Roundup, December 2025: The Net Pricing Drug Channel (#NPDC) Era, LillyDirect, My $0.02 on New MFPs, PBMs in Medicaid—and DCLF 2026

›
By Adam J. Fein, Ph.D. Happy New Year, everyone! As always, thank you for welcoming Drug Channels into your inboxes, browsers, and apps. ...
Tuesday, December 16, 2025

340B Hit $81 Billion in 2024: Why CMS and the IRA Are Poised to Cool the Program’s Runaway Growth (VIDEO)

›
Yesterday, I published 340B Hit $81 Billion in 2024 (+23%): Why CMS and the IRA Are Poised to Cool the Program’s Runaway Growth . For those ...
Monday, December 15, 2025

340B Hit $81 Billion in 2024 (+23%): Why CMS and the IRA Are Poised to Cool the Program’s Runaway Growth

›
By Adam J. Fein, Ph.D. Whoa. The 340B Drug Pricing Program has once again given new meaning to the word “skyrocketing.” For 2024, discount...
Wednesday, December 10, 2025

Who Will Pay for Prescription Drugs in 2033: DCI’s Takeaways from the Latest Government Forecasts (rerun)

›
This week, I’m rerunning some popular posts while I prepare for Friday's live video webinar: Drug Channels Outlook 2026 . Click here t...
Tuesday, December 02, 2025

List Price Reductions Will Deflate the Gross-to-Net Bubble–and Threaten Pharmacy and 340B Profits from IRA-Negotiated Drugs

›
By Adam J. Fein, Ph.D. Contrary to popular belief, the Inflation Reduction Act’s (IRA) maximum fair prices (MFPs) could temporarily boost p...
Thursday, November 13, 2025

Medicare Part D 2026: Preferred Networks Vanish as the PDP Market Collapses

›
By Adam J. Fein, Ph.D. As I’ve been warning for years, the Inflation Reduction Act of 2022 (IRA) has nearly obliterated the stand-alone Med...
Tuesday, October 28, 2025

Drug Channels News Roundup, October 2025: Vertical Integration Woes, AFPs Gone Wild, Part D’s Decline, 340Bloat, and Dr. G’s ACIP Haunting

›
By Adam J. Fein, Ph.D. Eeek! It’s time for the Drug Channel s Halloween roundup of terrifying tales from the dark corners of the healthcare...
Tuesday, September 30, 2025

Drug Channels News Roundup, September 2025: Mark Cuban Wins (Again), Biosimilar Pricing Double Standards, Part D Collapse, Fresh 340B Facts, and The Pitt

›
By Adam J. Fein, Ph.D. Autumn is here! Curl up with your Labubu’s favorite pumpkin-spiced blog and savor these stories harvested from the g...
Tuesday, September 23, 2025

Who Will Pay for Prescription Drugs in 2033: DCI’s Takeaways from the Latest Government Forecasts

›
Over the summer, the boffins at the Centers for Medicare & Medicaid Services (CMS) released the latest projections for U.S. spending on ...
Tuesday, June 24, 2025

Drug Channels News Roundup, June 2025: PBM Rebate Flow, 340B’s 2024 Boom, IRA Fallout, MFN Legal Risks—and Mark Cuban’s PBM Rant

›
Happy 249th birthday, America! Before you launch your July 4 festivities, Drug Channels humbly offers some fact-based fireworks to heal our...
Tuesday, June 17, 2025

The Top Pharmacy Benefit Managers of 2024: Market Share and Key Industry Developments (rerun)

›
This week, I’m rerunning some popular posts while I prepare for Friday’s live video webinar: What’s Next for Retail Pharmacy: Data, Debate,...